Petros Pharmaceuticals, Inc.
PTPI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815903
No open-market purchases or sales by Petros Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Petros Pharmaceuticals, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +2 vs. Q3 2021
- Shares held
- 1.08M
- +262.8K (+32.3%) vs. Q3 2021
- Total value
- $3.58M
- +$1.76M (+96.2%) vs. Q3 2021
- New holders
- 9
- 6 more added
- Sold out
- 7
- 4 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTPI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 15 | $77.6K |
| Q4 2024 | 9 | $38.5K |
| Q3 2024 | 11 | $59.2K |
| Q2 2024 | 12 | $94.9K |
| Q1 2024 | 13 | $94.9K |
| Q4 2023 | 16 | $164.7K |
| Q3 2023 | 14 | $170.6K |
| Q2 2023 | 14 | $214.3K |
| Q1 2023 | 9 | $42.7K |
| Q4 2022 | 10 | $90.6K |
| Q3 2022 | 13 | $355.0K |
| Q2 2022 | 16 | $558.0K |
| Q1 2022 | 19 | $1.30M |
| Q4 2021 | 21 | $3.58M |
| Q3 2021 | 19 | $1.82M |
| Q2 2021 | 22 | $3.02M |
| Q1 2021 | 20 | $4.23M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Petros Pharmaceuticals, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Schonfeld Strategic Advisors LLC | 342,900 | $1.14M | 0.01% | +342,900 | New |
| Marshall Wace, LLP | 244,080 | $813.0K | 0.00% | +244,080 | New |
| Vanguard Group Inc | 151,247 | $504.0K | 0.00% | +41,534+37.9% | Added |
| Susquehanna International Group, LLP | 67,640 | $225.0K | 0.00% | +67,640 | New |
| Geode Capital Management, LLC | 58,785 | $195.0K | 0.00% | +35,060+147.8% | Added |
| Virtu Financial LLC | 53,019 | $177.0K | 0.02% | +53,019 | New |
| State Street Corp | 44,600 | $149.0K | 0.00% | +44,600 | New |
| Squarepoint Ops LLC | 35,814 | $119.0K | 0.00% | +35,814 | New |
| BlackRock Inc. | 19,559 | $65.0K | 0.00% | +937+5.0% | Added |
| Northern Trust Corp | 13,705 | $46.0K | 0.00% | +13,705 | New |
| Two Sigma Advisers, LP | 12,000 | $40.0K | 0.00% | +12,000 | New |
| Two Sigma Securities, LLC | 10,494 | $35.0K | 0.01% | +10,494 | New |
| Emfo, LLC | 10,000 | $33.0K | 0.03% | −18,000−64.3% | Reduced |
| Morgan Stanley | 3,869 | $13.0K | 0.00% | +3,700+2,189.3% | Added |
| Tower Research Capital LLC (TRC) | 3,216 | $11.0K | 0.00% | +3,116+3,116.0% | Added |
| UBS Group AG | 2,049 | $7.00K | 0.00% | −1,563−43.3% | Reduced |
| Newbridge Financial Services Group, Inc. | 1,200 | $4.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1,135 | $3.00K | 0.00% | −700−38.1% | Reduced |
| Royal Bank of Canada | 57 | $0 | 0.00% | −1,943−97.2% | Reduced |
| Wells Fargo & Company | 60 | $0 | 0.00% | +19+46.3% | Added |
| First Manhattan Co | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Shay Capital LLC | 0 | $0 | 0.00% | −277,737−100.0% | Sold out |
| NorthRock Partners, LLC | 0 | $0 | 0.00% | −115,295−100.0% | Sold out |
| CM Management, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −54,347−100.0% | Sold out |
| Platform Technology Partners | 0 | $0 | 0.00% | −44,000−100.0% | Sold out |
| Neville Rodie & Shaw Inc | 0 | $0 | 0.00% | −21,875−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −10,367−100.0% | Sold out |